Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-1013 in healthy smokers
NCT07215923Phase 1Recruiting
- Sponsor
- Antidote Therapeutics, Inc.
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ATI-1013 in thromboangiitis obliterans (TAO) and nicotine dependence (3 cohorts), sponsored by Antidote Therapeutics, Inc. Primary endpoints: Incidence of all adverse events (AEs) and Development of Anti-Drug Antibodies. Started Oct 2025; status: recruiting.
02
Drugs
ATI-1013
03
Conditions
thromboangiitis obliterans (TAO)nicotine dependence
Beyond the preview
Go deeper on NCT07215923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215923.